foxo4-dri peptide senolytic animal model 2023 UK | Research FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI 10mg FOXO4 DRI alleviates RIPF. (A) Representative Western blot for the Download Scientific Diagram The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity. Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine FOXO4 an overview ScienceDirect Topics
Pay in 4 interest-free payments of $6.66 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13




